Skip to main content
Skip to footer
Home
News Channels
Antibodies
Proteins and Peptides
Vaccines
DNA RNA and Cells
Small Molecules
More News
All News
Reports
Press Room
Contact Us
About Us
Search ...
All Categories
Antibodies
DNA RNA and Cells
More News
Proteins and Peptides
Small Molecules
Vaccines
Results
Biosimilar Antibodies & Proteins
Mar 2024
CD38-Targeted Antibody & Cell Therapy Pipeline Review
300,00€
Mar 2024
2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
130,00€
Mar 2024
Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA
250,00€
Jul 2023
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review
300,00€
Jul 2023
Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists
400,00€
Jul 2023
Adalimumab (Humira) Biosimilars Pipeline Review
400,00€
Jun 2023
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review
300,00€
Jun 2023
Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review
300,00€
Jun 2023
Ranibizumab (Lucentis) Biosimilars Pipeline Review
300,00€
Jun 2023
Aflibercept (Eylea) Biosimilars Pipeline Review
300,00€
1
2
→
Search ...
Report categories
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells
Drug the Undruggable Technologies
Immuno-Oncology
mRNA Vaccines & Therapeutics
NK Cells & CAR Macrophages
Pipeline Database
RNA-Targeted Therapeutics
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Antibodies
Therapeutic Proteins & Peptides